Incorporation of HIPEC into a high volume ovarian cancer program: Initial results and outcomes.

person Aliza L. Leiser Rutgers Cancer Institute of New Jersey, New Brunswick, NJ info_outline Aliza L. Leiser, Eugenia Girda, Ruth D. Stephenson, Mihae Song, Alexandre Buckley de Meritens, Lorna Rodriguez-Rodriguez

Authors person Aliza L. Leiser Rutgers Cancer Institute of New Jersey, New Brunswick, NJ info_outline Aliza L. Leiser, Eugenia Girda, Ruth D. Stephenson, Mihae Song, Alexandre Buckley de Meritens, Lorna Rodriguez-Rodriguez Organizations Rutgers Cancer Institute of New Jersey, New Brunswick, NJ Abstract Disclosures Research Funding Other Background: HIPEC showed a progression free survival when incorporated into interval cytoreductive surgery for ovarian cancer patients in a recent phase lll trial. This has led to a paradigm shift at many institutions and the consideration of HIPEC. The goal of this study is to report on the initiation of this program and change in practice at a high volume cancer center over a period of 1 year. Methods: Reviewed surgical cases from 1/2018 through 1/2019 where patients were thought to have a primary ovarian or fallopian tube cancer. Variables included age, stage, histology, primary or interval debulking surgery, number of neoadjuvant (NAJ) chemotherapy cycles. HIPEC patients were selected out and variables examined included intraoperative procedures, optimal cytoreduction, type of chemotherapy administered, postoperative complications, and ability to receive consolidation chemotherapy. Results: 35 cases where ovarian cancer known or suspected preoperatively. 23 patients had primary surgery consisting of tah/bso/surgical staging/tumor debulking. 0/23 of these patients were offered HIPEC chemotherapy as an upfront strategy. 12 patients received neoadjuvant chemotherapy for recurrent (2) or advanced (10) disease. 11/12 of these patients proceeded to an interval surgery. 6/11 (54%) were planned for HIPEC. This was aborted in 1/6 because of thrombocytopenia. 5/6 patients went on to receive HIPEC. They received 3-6 cycles of NAJ chemotherapy, platinum and taxane. 3/5 also received preoperative Avastin. All had R0 resection. 1 patient had a bowel resection. Either carboplatin or cisplatin was used for HIPEC over 90 minutes. 2/5 patients had postoperative G2-3 cytopenias. 3/5 patients were able to receive consolidation chemotherapy, 2 of them within six weeks of surgery and with Avastin containing regimens. Conclusions: In a large volume center initiating a HIPEC ovarian cancer program in less than one years’ time, HIPEC was offered to 50% of patients undergoing interval debulking for Stage III or IV serous ovarian cancer after NAJ chemotherapy and in rare cases for patients with recurrent cancer planned for cytoreduction. Patients may go on to receive postoperative chemotherapy but may have prolonged cytopenias and consolidation therapy delays. HIPEC was not incorporated into an upfront surgical strategy. Stage Serous (invasive)Histology Primary Surgery NAJ/Interval HIPEC I 10 0/10 10/10 (100%) 0/10 0 II 5 1/5 (20%) 5/5 (100%) 0/5 0 III 13 12/13 (92%) 8/13 (61%) 5/13 (38%) 1/5(20%) IV 5 4/5 (100%) 0/5 5/5 (100%) 3/5 (60%) Recurrent 2 2/2 (100%) 0/2 2/2 (100%) 2/2 (100%)